In preclinical models, Bryostatin-1 has demonstrated single-agent activity against B16 melanoma, M5076 reticulum sarcoma and L10A B-cell lymphoma [50] and has been shown to disrupt cyclin B-CDK1 complex formation and activity by several different mechanisms [51], [52]. Here, CDK1 is linked to melanoma.